Table 2.

Oncological outcome at 6-yr follow-up

	Unadjusted analyses				Adjustment A		Adjustment B
	RALP	RRP	RR (95% CI)	p value	RR (95% CI)	p value	RR (95% CI)	p value
All patients
Residual diseasea	37/1504 (2)	13/596 (2)	1.13 (0.66; 1.93)	0.7	0.97 (0.55; 1.72)	0.9	0.69 (0.31; 1.55)	0.4
Missing	41	37			129		192
BCRb	218/1538 (14)	98/631 (16)	0.91 (0.72; 1.16)	0.5	0.89 (0.65; 1.21)	0.5	0.86 (0.57; 1.29)	0.5
Missing	7	2			88		151
Not curedc	334/1492 (22)	131/611 (21)	1.04 (0.76; 1.43)	0.8	0.97 (0.71; 1.32)	0.9	0.86 (0.56; 1.33)	0.5
Missing	53	22			156		218
Experienced surgeons
Residual diseasea	51/2203 (2)	19/681 (3)	0.83 (0.51; 1.36)	0.5	0.75 (0.45; 1.26)	0.3	0.46 (0.23; 0.93)	0.03
Missing	48	38			166		236
BCRb	321/2244 (14)	113/717 (16)	0.91 (0.73; 1.12)	0.4	0.93 (0.71; 1.23)	0.6	0.77 (0.56; 1.06)	0.1
Missing	7	2			121		191
Not curedc	483/2174 (22)	157/687 (23)	0.99 (0.75; 1.3)	0.9	0.96 (0.73; 1.25)	0.8	0.82 (0.6; 1.11)	0.2
Missing	77	22			210		279

BCR = biochemical recurrence; CI = confidence interval; PSA = prostate-specific antigen; RALP = robot-assisted laparoscopic prostatectomy; RR = relative risk; RRP = retropubic radical prostatectomy.

Adjustment A: pathology T stage, pathology Gleason score, preoperative PSA level, pathology prostate weight.

Adjustment B: same as adjustment A plus surgeon annual volume and surgeon prior experience.

^aPSA > 0.25 ng/ml at 3 mo.

^bPSA < 0.25 ng/ml at 3 mo and PSA > 0.25 ng/ml at 1, 2, or 6 yr of follow-up.

^cPSA > 0.25 ng/ml at any time or radiotherapy, chemotherapy, or hormone therapy at 1, 2, or 6 yr of follow-up.